摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-fluoro-N-[4-(trifluoromethyl)benzyl]benzamide

中文名称
——
中文别名
——
英文名称
4-fluoro-N-[4-(trifluoromethyl)benzyl]benzamide
英文别名
4-fluoro-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide
4-fluoro-N-[4-(trifluoromethyl)benzyl]benzamide化学式
CAS
——
化学式
C15H11F4NO
mdl
——
分子量
297.25
InChiKey
YKQAWQITONYURX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • CYCLIC AMIDES, ACTEAMIDES AND UREAS USEFUL AS POTASSIUM CHANNEL OPENERS
    申请人:Acousia Therapeutics GmbH
    公开号:EP3366683A1
    公开(公告)日:2018-08-29
    The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula I, wherein - n = 0 or 1 , - RL is a substituent selected from the group consisting of unsubstituted or substituted cycloalkyl groups, alkylcycloalkyl groups, aryl groups, arylalkyl groups and arylcycloalkyl groups, which optionally contain heteroatoms, and - RR is a substituent selected from the group consisting of unsubstituted or substituted aryl groups, alkylaryl groups, and arylalkyl groups, which optionally contain heteroatoms, - or a stereoisomer, a tautomer, a prodrug or a salt, preferably pharmaceutically acceptable salt thereof.
    本发明公开了可用作通道开放剂,特别是用作 Kv7.4 通道开放剂的新型化合物。这些新型化合物是符合式 I 的化合物、 式中 - n = 0 或 1 、 - RL 是选自未取代或取代的环烷基、烷基环烷基、芳基、芳烷基和芳基环烷基(可选含有杂原子)的取代基,以及 - RR 是一个取代基,选自由未取代或取代的芳基、烷芳基和芳烷基组成的组,其中可选含有杂原子、 - 或其立体异构体、同系物、原药或盐,最好是药学上可接受的盐。
  • PENTACYCLOTHIENYL AND INDANYL UREA DERIVATIVES AS POTASSIUM CHANNEL OPENERS
    申请人:Acousia Therapeutics GmbH
    公开号:EP3567034A1
    公开(公告)日:2019-11-13
    The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula I, wherein - n = 0 or 1, - RL is a substituent selected from the group consisting of unsubstituted or substituted cycloalkyl groups, in particular bicycloalkyl groups, unsubstituted or substituted phenyl groups, unsubstituted or substituted thienyl groups or cyclopentathienyl groups, and unsubstituted or substituted indanyl groups, which optionally contain heteroatoms, and - RR is a substituent selected from the group consisting of unsubstituted or substituted phenyl groups or unsubstituted or substituted benzyl groups, which optionally contain heteroatoms, - or a stereoisomer, a tautomer, a prodrug or a salt, preferably pharmaceutically acceptable salt thereof.
    本发明公开了可用作通道开放剂,特别是用作 Kv7.4 通道开放剂的新型化合物。这些新型化合物是符合式 I 的化合物、 其中 - n = 0 或 1、 - RL 是一个取代基,选自由未取代或取代的环烷基(尤其是双环烷基)、未取代或取代的苯基、未取代或取代的噻吩基或环戊二烯基和未取代或取代的基组成的组,这些基团可选择含有杂原子,以及 - RR 是一个取代基,选自由未取代或取代的苯基或未取代或取代的苄基(可选含有杂原子)组成的组、 - 或其立体异构体、同系物、原药或盐,最好是药学上可接受的盐。
  • Compounds useful as potassium channel openers
    申请人:ACOUSIA THERAPEUTICS GMBH
    公开号:US11034665B2
    公开(公告)日:2021-06-15
    The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula I, wherein n=0 or 1, RL is a substituent selected from the group consisting of unsubstituted or substituted cycloalkyl groups, in particular bicycloalkyl groups, unsubstituted or substituted phenyl groups, unsubstituted or substituted thienyl groups or cyclopentathienyl groups, and unsubstituted or substituted indanyl groups, which optionally contain heteroatoms, and RR is a substituent selected from the group consisting of unsubstituted or substituted phenyl groups or unsubstituted or substituted benzyl groups, which optionally contain heteroatoms, or a stereoisomer, a tautomer, a prodrug or a salt, preferably pharmaceutically acceptable salt thereof.
    本发明公开了可用作通道开放剂,特别是用作 Kv7.4 通道开放剂的新型化合物。这些新型化合物是符合式 I 的化合物、 式中 n=0 或 1、 RL 是一个取代基,选自由未取代或取代的环烷基(尤其是双环烷基)、未取代或取代的苯基、未取代或取代的噻吩基或环戊二烯基,以及未取代或取代的基组成的组,这些基团可选择含有杂原子,以及 RR 是一个取代基,选自由未取代或取代的苯基或未取代或取代的苄基(可选含有杂原子)组成的组、 或其立体异构体、同系物、原药或盐,最好是药学上可接受的盐。
  • NOVEL COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS
    申请人:Acousia Therapeutics GmbH
    公开号:EP3484863A2
    公开(公告)日:2019-05-22
  • [EN] NOVEL COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS<br/>[FR] NOUVEAUX COMPOSÉS UTILES EN TANT QU'AGENTS D'OUVERTURE DES CANAUX POTASSIQUES
    申请人:ACOUSIA THERAPEUTICS GMBH
    公开号:WO2018158256A2
    公开(公告)日:2018-09-07
    The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula (I), wherein - n = 0 or 1, - RL is a substituent selected from the group consisting of unsubstituted or substituted cycloalkyl groups, in particular bicycloalkyl groups, unsubstituted or substituted phenyl groups, unsubstituted or substituted thienyl groups or cyclopentathienyl groups, and unsubstituted or substituted indanyl groups, which optionally contain heteroatoms, and - RR is a substituent selected from the group consisting of unsubstituted or substituted phenyl groups or unsubstituted or substituted benzyl groups, which optionally contain heteroatoms, - or a stereoisomer, a tautomer, a prodrug or a salt, preferably pharmaceutically acceptable salt thereof.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫